Sanofi acquires over-the-counter rights for Cialis

by The Associated Press
Viagra pill

French drugmaker Sanofi is buying the rights to seek approval for a version of the erectile dysfunction drug Cialis that customers would be able to buy without a doctor's prescription.

Sanofi will acquire the rights from its U.S. counterpart Eli Lilly and Co. for the United States, Europe, Canada and Australia under the deal.

Lilly spokeswoman Celeste Stanley says they don't expect to launch such a version before 2018.

Cialis is currently sold only through prescription. It brought in $2.16 billion in last year, but it will lose patent protection in the U.S. and other markets in 2017. That will expose the drug to competition from cheaper, .

Terms of the Sanofi-Lilly deal were not disclosed.

5 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

Pfizer, Teva reach deal to allow generic Viagra

Dec 17, 2013

Pfizer says it reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017.

Eli Lilly to buy part of Novartis for $5.4 bn

Apr 22, 2014

US pharmaceutical giant Eli Lilly said Tuesday it has reached an agreement to acquire the animal health division of Novartis of Switzerland for $5.4 billion (3.9 billion euros).

Eli Lilly 2013 profit forecast tops expectations

Jan 04, 2013

(AP)—Eli Lilly and Co. said Friday its 2013 earnings will grow more than Wall Street expects, even though the drugmaker will lose U.S. patent protection for two more key products this year.

FDA approves first generic versions of Cymbalta

Dec 11, 2013

The Food and Drug Administration says it has approved the first generic versions of the blockbuster antidepressant drug Cymbalta, offering lower-cost access to one of the most widely prescribed treatments for depression, ...

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

10 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments